Cue Biopharma, Inc. (CUE)
28.74
+0.74
(+2.64%)
USD |
NASDAQ |
Sep 11, 16:00
28.83
+0.09
(+0.31%)
After-Hours: 20:00
Cue Biopharma Debt to Equity Ratio : 3.813 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.813 |
| March 31, 2026 | 0.1592 |
| December 31, 2025 | 0.1588 |
| September 30, 2025 | 0.466 |
| June 30, 2025 | 0.4204 |
| March 31, 2025 | 1.083 |
| December 31, 2024 | 0.5072 |
| September 30, 2024 | 0.375 |
| June 30, 2024 | 0.5209 |
| March 31, 2024 | 0.4327 |
| December 31, 2023 | 0.3963 |
| September 30, 2023 | 0.3838 |
| June 30, 2023 | 0.3922 |
| March 31, 2023 | 0.34 |
| December 31, 2022 | 0.2941 |
| September 30, 2022 | 0.3863 |
| June 30, 2022 | 0.3325 |
| March 31, 2022 | 0.3094 |
| Date | Value |
|---|---|
| December 31, 2021 | 0.1535 |
| September 30, 2021 | 0.0572 |
| June 30, 2021 | 0.0668 |
| March 31, 2021 | 0.0872 |
| December 31, 2020 | 0.0906 |
| September 30, 2020 | 0.0937 |
| June 30, 2020 | 0.1052 |
| March 31, 2020 | 0.1041 |
| December 31, 2019 | 0.1062 |
| September 30, 2019 | 0.2607 |
| June 30, 2019 | 0.3857 |
| March 31, 2019 | 0.3473 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Nurix Therapeutics, Inc. | 0.1444 |
| Monte Rosa Therapeutics, Inc. | 0.078 |
| Xilio Therapeutics, Inc. | 0.0872 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 30.71M |
| Total Liabilities (Quarterly) | 28.40M |
| Shareholders Equity (Quarterly) | 2.31M |
| Current Ratio | 1.255 |
| Net Debt Paydown Yield | -0.20% |